MLi-2 is primarily utilized in the field of medicinal chemistry and drug development, particularly in the study of neurodegenerative diseases. It serves as a potent and selective inhibitor of leucine-rich repeat kinase 2 (LRRK2), an enzyme implicated in the pathogenesis of Parkinson's disease. By inhibiting LRRK2, MLi-2 helps researchers understand the enzyme's role in disease progression and evaluate its potential as a therapeutic target. This compound is also used in preclinical studies to assess the efficacy and safety of LRRK2 inhibition, paving the way for the development of novel treatments for Parkinson's and related disorders. Additionally, MLi-2 is employed in biochemical assays to investigate kinase signaling pathways and their impact on cellular processes.